Not yet recruiting Phase 2 NCT07550231

Determining the Optimal Dose of AD-211 in Patients With Osteoarthritis of the Knee

Phase 2 – studying effectiveness and dosage

Conditions: Osteoarthritis of the Knees

Sponsor: Addpharma Inc.

trial.available_in:

БГ

Overview

The purpose of this study is to determine the optimal dose of AD-211 in patients with osteoarthritis of the knee.

Description

Osteoarthritis of the knee

Who can participate

Inclusion Criteria: * Signed informed consent * Patients with osteoarthritis of the Knee * Other inclusions applied Exclusion Criteria: * Patients with secondary osteoarthritis of the knee * Other exclusions applied

Interventions

AD-211-L

DRUG

AD-211-M

DRUG

AD-211-H

DRUG

AD-2113

DRUG

Placebo to AD-211-L/M

DRUG

Placebo to AD-211-H

DRUG

Placebo to AD-2113

DRUG

Locations

Location information is not available.

Status

Not yet recruiting

Phase

Phase 2

Study type

INTERVENTIONAL

Sex

Male and female

Minimum age

19 Years

Maximum age

75 Years

Healthy volunteers

Start date

01.06.2026

Completion date

01.03.2027

Registry ID

NCT07550231

Source

clinicaltrials.gov

trial.inquiry_btn

Information is automatically extracted from ClinicalTrials.gov. Consult your doctor before taking action.